Lisa B E Shields, Hannah S Hust, Gregory E Cooper, Theresa Kluthe, Rachel N Hart, Andrew P Thaliath, Brandon C Dennis, Stephanie W Freeman, Jessica F Cain, Whoy Y Shang, Kendall M Wasz, Adam T Orr, Christopher B Shields, Shirish S Barve, Kenneth G Pugh
{"title":"Experience with donanemab over a 1-year period: observations of side effects and compliance from a regional specialty medical center.","authors":"Lisa B E Shields, Hannah S Hust, Gregory E Cooper, Theresa Kluthe, Rachel N Hart, Andrew P Thaliath, Brandon C Dennis, Stephanie W Freeman, Jessica F Cain, Whoy Y Shang, Kendall M Wasz, Adam T Orr, Christopher B Shields, Shirish S Barve, Kenneth G Pugh","doi":"10.1002/dad2.70438","DOIUrl":"https://doi.org/10.1002/dad2.70438","url":null,"abstract":"<p><strong>Introduction: </strong>The anti-amyloid monoclonal antibody donanemab (Kisunla™) treats patients with mild cognitive impairment or mild Alzheimer's disease.</p><p><strong>Methods: </strong>This study highlights 51 patients who received at least one donanemab infusion at our memory center between October 4, 2024 and October 3, 2025.</p><p><strong>Results: </strong>Of the 48 patients who underwent at least one surveillance brain MRI after starting donanemab, 10 (20.8%) had ARIA detected. ε4 carriers more frequently displayed amyloid-related imaging abnormalities (ARIA-cortical superficial hemosiderosis/microhemorrhages [ARIA-H] and/or ARIA-edema/effusion) (<i>p</i> = 0.033) and ARIA-H (<i>p</i> = 0.020) compared to ε4 non-carriers. No patients developed symptomatic ARIA. Seven (13.7%) patients experienced infusion-related side effects. Eight (15.7%) patients discontinued donanemab due to ARIA progression (5), severe infusion reactions (2), and need for anticoagulants (1).</p><p><strong>Discussion: </strong>Donanemab may be safely used in a real-world setting with structured monitoring. ARIA was observed in 20.8% of patients in this implementation cohort. Larger-scale multicenter data are needed to benchmark rates.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70438"},"PeriodicalIF":4.4,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Erin-Leigh Gallop, Pooja Kondeti, Hannah Gardener, Tatjana Rundek, Jose Gutierrez, Mitchell S V Elkind, Clinton B Wright, Bonnie Levin, Lily Wang, Christian Agudelo, Stephanie Assuras, Vanessa Guzman, Tali Elfassy
{"title":"Life's Essential 8™ and incident dementia in an urban cohort: Findings from the Northern Manhattan Study.","authors":"Erin-Leigh Gallop, Pooja Kondeti, Hannah Gardener, Tatjana Rundek, Jose Gutierrez, Mitchell S V Elkind, Clinton B Wright, Bonnie Levin, Lily Wang, Christian Agudelo, Stephanie Assuras, Vanessa Guzman, Tali Elfassy","doi":"10.1002/dad2.70444","DOIUrl":"10.1002/dad2.70444","url":null,"abstract":"<p><strong>Introduction: </strong>The American Heart Association's Life's Essential 8™ (LE8) defines cardiovascular health (CVH) using eight behavioral and clinical metrics. We examined the association between CVH and incident dementia.</p><p><strong>Methods: </strong>We used data from 920 dementia-free participants of the Northern Manhattan Study. LE8 scores (range: 0-100) were calculated from information on clinical and behavioral characteristics. Dementia was adjudicated by expert clinicians using neuropsychological assessments and clinical records. We used Cox proportional hazards models to determine associations adjusting for age, sex, race/ethnicity, education, and insurance.</p><p><strong>Results: </strong>Mean age was 64 years, 60% of participants were female, 65% were Hispanic, and mean LE8 score was 60. Over 9 years, 175 participants developed dementia. Each 10-unit decrement in LE8 score was associated with a greater risk of dementia (hazard ratio [HR]: 1.33; 95% confidence interval [CI]: 1.17-1.51).</p><p><strong>Discussion: </strong>CVH is important for brain health, and our results support interventions aimed at improving CVH for prevention of dementia.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70444"},"PeriodicalIF":4.4,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eleni Palpatzis, Carmen M Colceriu, Mahnaz Shekari, Muge Akinci, Marc Suárez-Calvet, Oriol Grau-Rivera, Gonzalo Sánchez-Benavides, Juan Domingo Gispert, Eider M Arenaza-Urquijo
{"title":"Regional amyloid accumulation, post-traumatic distress, and intrusive symptoms in cognitively unimpaired older adults at risk for Alzheimer's.","authors":"Eleni Palpatzis, Carmen M Colceriu, Mahnaz Shekari, Muge Akinci, Marc Suárez-Calvet, Oriol Grau-Rivera, Gonzalo Sánchez-Benavides, Juan Domingo Gispert, Eider M Arenaza-Urquijo","doi":"10.1002/dad2.70410","DOIUrl":"https://doi.org/10.1002/dad2.70410","url":null,"abstract":"<p><strong>Introduction: </strong>In preclinical Alzheimer's disease (AD), early pathology may heighten vulnerability to psychiatric symptoms. We examined whether Aβ accumulation in cognitive-emotional regions was associated with post-pandemic psychiatric symptoms.</p><p><strong>Methods: </strong>This prospective cohort study included 115 cognitively unimpaired ALzheimer's and FAmilies participants (69 [60%] women, mean [SD] age 64.9 [4.8] years). Amyloid beta (Aβ) change was examined in anterior cingulate, posterior cingulate, superior parietal, medial orbitofrontal gyri, and insula using two [18F]flutemetamol positron emission tomography (PET) scans. Outcomes were pandemic-related post-traumatic distress (Impact of Events Scale Revised [IES-R]; total, intrusive, avoidance, and hyperarousal symptoms) and anxious-depressive symptoms (Hospital Anxiety and Depression Scale [HADS]; mean follow-up: 3.62 years [SD = 0.68]). Linear regression and voxel-wise analyses were performed.</p><p><strong>Results: </strong>Aβ accumulation across anterior cingulate (<i>β</i> = 40.29, <i>p</i> = 0.036), posterior cingulate (<i>β</i> = 29.52, <i>p</i> = 0.012), superior parietal (<i>β</i> = 35.58, <i>p</i> = 0.036), and medial orbitofrontal gyri (<i>β</i> = 35.08, <i>p</i> = 0.036) was associated with post-pandemic intrusive symptoms only, independent of baseline anxious-depressive symptoms.</p><p><strong>Discussion: </strong>Aβ accumulation in cognitive-emotional regions may increase vulnerability to intrusive symptoms, highlighting their potential as early clinical markers in AD.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70410"},"PeriodicalIF":4.4,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joshua Flavell, Soohyun Lee, Caitlin A T McElligott, Felicia M Coleman, Amir Fazlollahi, Emily G McCann, Duy D Nguyen, Peter J Nestor
{"title":"Clinical tools to differentiate behavioral variant frontotemporal dementia from phenocopies.","authors":"Joshua Flavell, Soohyun Lee, Caitlin A T McElligott, Felicia M Coleman, Amir Fazlollahi, Emily G McCann, Duy D Nguyen, Peter J Nestor","doi":"10.1002/dad2.70452","DOIUrl":"https://doi.org/10.1002/dad2.70452","url":null,"abstract":"<p><strong>Introduction: </strong>Behavioral variant frontotemporal dementia (bvFTD) is often misdiagnosed, particularly in psychiatric phenocopies of the disease (phFTD). We compared the top-performing bvFTD-specific behavioral tools, identified in a prior systematic review, for differentiating bvFTD from phFTD.</p><p><strong>Methods: </strong>In this prospective diagnostic accuracy study, consecutively recruited participants with suspected bvFTD by a specialist physician completed nine bvFTD-specific tools at baseline with a blinded assessor. Final diagnoses were assigned by multidisciplinary consensus after follow-up. Diagnostic performance was assessed using receiver operating characteristic analyses.</p><p><strong>Results: </strong>Fifty-one participants were included (25 bvFTD, 26 phFTD). The Frontotemporal Dementia versus Primary Psychiatric Disorder (FTDvsPPD) checklist showed the best discrimination (area under the curve [AUC] 0.92), with 80.0% sensitivity and 96.2% specificity. The Social Behavior Observer Checklist (SBOC) performed next best (AUC 0.85). The Informant Based Questionnaire and Pick's Disease Scale showed moderate discrimination and other tools performed poorly.</p><p><strong>Discussion: </strong>Tools focused on clinician observation outperformed informant-reliant measures. The FTDvsPPD checklist showed the strongest rule-in and rule-out utility, while the SBOC provided useful rule-in support.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70452"},"PeriodicalIF":4.4,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cindy David Sarmento, Gabin Drouard, Toni T Saari, Aino Aaltonen, Aino Heikkinen, Mikaela Hukkanen, Teemu Palviainen, Sanna-Kaisa Herukka, Tarja Kokkola, Sari Kärkkäinen, Aarno Palotie, Valtteri Julkunen, Heiko Runz, Jaakko Kaprio, Miina Ollikainen, Eero Vuoksimaa
{"title":"Associations of proteomic and epigenetic aging clocks with Alzheimer's disease phenotypes: An exploratory analysis.","authors":"Cindy David Sarmento, Gabin Drouard, Toni T Saari, Aino Aaltonen, Aino Heikkinen, Mikaela Hukkanen, Teemu Palviainen, Sanna-Kaisa Herukka, Tarja Kokkola, Sari Kärkkäinen, Aarno Palotie, Valtteri Julkunen, Heiko Runz, Jaakko Kaprio, Miina Ollikainen, Eero Vuoksimaa","doi":"10.1002/dad2.70456","DOIUrl":"https://doi.org/10.1002/dad2.70456","url":null,"abstract":"<p><strong>Introduction: </strong>Proteomic aging clocks detect disease-related systemic and organ-specific changes and are easily accessible by minimally invasive blood draws. However, their potential in Alzheimer's disease (AD) assessment remains unestablished.</p><p><strong>Methods: </strong>We investigated associations of proteomic and epigenetic clocks with AD-related blood-based biomarkers and cognitive tests. Omics were generated from blood samples of 153 cognitively unimpaired individuals (average age 62 years); blood biomarkers and cognition were measured approximately nine years after.</p><p><strong>Results: </strong>Proteomic clocks explained up to 23% of variance in cognitive and biomarker measures not explained by epigenetics. Accelerated systemic and brain-specific proteomic aging were linked to poorer cognition and higher levels of plasma neurofilament light chain. Exploratory interaction analyses suggested weaker proteomic aging-cognition associations in individuals with higher genetic liability for diabetes.</p><p><strong>Discussion: </strong>Our study illustrates the potential of plasma proteomic clocks in detecting AD-related phenotypes. However, co-morbidities possibly constitute confounding factors, compromising the performance of proteomic aging models.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70456"},"PeriodicalIF":4.4,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sitong Zhou, Jacob Conston, Nopparat Suthprasertporn, Ramses Denis-Romero, Jacopo Di Lucente, Jeannine L White, Michelle M Mielke, Danielle Harvey, Kumar B Rajan, David K Johnson, Myriam Fornage, Charles DeCarli, Jason D Hinman, Lee-Way Jin
{"title":"Harmonizing biofluid specimen collection and biomarker quantification in Diverse Vascular Contributions to Cognitive Impairment and Dementia (DVCID) study.","authors":"Sitong Zhou, Jacob Conston, Nopparat Suthprasertporn, Ramses Denis-Romero, Jacopo Di Lucente, Jeannine L White, Michelle M Mielke, Danielle Harvey, Kumar B Rajan, David K Johnson, Myriam Fornage, Charles DeCarli, Jason D Hinman, Lee-Way Jin","doi":"10.1002/dad2.70435","DOIUrl":"10.1002/dad2.70435","url":null,"abstract":"<p><strong>Introduction: </strong>Multicenter clinical studies inherently face challenges in maintaining consistency across sites. Here we share the design and implementation of standard operating procedures (SOPs) for the Diverse Vascular Contributions to Cognitive Impairment and Dementia (DVCID) study.</p><p><strong>Methods: </strong>The Repository Core implements harmonized protocols for biospecimen collection and preparation. Pre-, intra-, and post-analytical factors influencing sample integrity and data reliability are addressed. Stringent measures are applied to obtain reproducible biomarker data.</p><p><strong>Results: </strong>Rigorous post-analytical quality control ensures assay variabilities within acceptable limits. Interim analyses, presented as proof of concept, show differences in selected plasma biomarkers across sex and race/ethnicity after covariate adjustment. These efforts establish a strong foundation for the high-quality data generated in DVCID, supporting reliability of downstream analyses.</p><p><strong>Discussion: </strong>This work demonstrates a standardized framework to enhance data comparability, aiming to inform and facilitate future multicenter biomarker studies. Interim findings also highlight the potential need for ethnoracially tailored cut-offs when interpreting blood-based biomarker data.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70435"},"PeriodicalIF":4.4,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482173/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Francesco Pierotti, Carmen Morinelli, Valentina Moschini, Sonia Padiglioni, Giulia Giacomucci, Salvatore Mazzeo, Silvestro Micera, Andrea Bandini, Valentina Bessi
{"title":"Automated differentiation of non-fluent and logopenic primary progressive aphasia in Italian speakers using acoustic and linguistic speech measures.","authors":"Francesco Pierotti, Carmen Morinelli, Valentina Moschini, Sonia Padiglioni, Giulia Giacomucci, Salvatore Mazzeo, Silvestro Micera, Andrea Bandini, Valentina Bessi","doi":"10.1002/dad2.70450","DOIUrl":"10.1002/dad2.70450","url":null,"abstract":"<p><strong>Introduction: </strong>Differentiating the nonfluent/agrammatic and logopenic variants of primary progressive aphasia (PPA; nfvPPA and lvPPA, respectively) remains clinically challenging due to overlapping subtle speech and language impairments. We investigated whether automated connected speech analysis can support differential diagnosis.</p><p><strong>Methods: </strong>We analyzed connected speech from 84 Italian speakers with PPA (23 nfvPPA, 23 semantic variant [svPPA], and 38 lvPPA) using a picture-description task. Prosodic, phonological, and morphosyntactic features were extracted. Machine-learning classifiers were trained for binary (lvPPA vs. nfvPPA) and multiclass (lvPPA, nfvPPA, svPPA) classification. Explainability analyses identified key features.</p><p><strong>Results: </strong>The combination of speech and language features effectively discriminated among PPA variants. Binary classification reached 81.67% accuracy, while multiclass classification reached 63.86% accuracy. Noun rate, local jitter, articulation rate, and total pauses were among the most informative features.</p><p><strong>Discussion: </strong>Automated analysis of connected speech provides objective linguistic biomarkers that enhance diagnostic accuracy and support reliable differentiation of PPA variants in clinical practice.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70450"},"PeriodicalIF":4.4,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13474157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148765515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jun Zhang, Brian J Burkett, Christopher G Schwarz, Nur Dizdar, Matthew P Johnson, Cem Bilgin, Bradley J Kemp, Jolanta M Durski, Val Lowe, Derek R Johnson
{"title":"Inter-software variability of Centiloid quantification in amyloid PET: A head-to-head comparison of five software platforms.","authors":"Jun Zhang, Brian J Burkett, Christopher G Schwarz, Nur Dizdar, Matthew P Johnson, Cem Bilgin, Bradley J Kemp, Jolanta M Durski, Val Lowe, Derek R Johnson","doi":"10.1002/dad2.70443","DOIUrl":"https://doi.org/10.1002/dad2.70443","url":null,"abstract":"<p><strong>Introduction: </strong>Centiloid (CL) scaling standardizes amyloid positron emission tomography (PET) quantification across tracers and platforms; however, variability across software implementations may affect diagnostic classification. This study evaluated inter-software variability and diagnostic performance across five platforms using identical <sup>1</sup> <sup>8</sup>F-florbetapir datasets.</p><p><strong>Methods: </strong>Retrospectively, 192 patients undergoing <sup>1</sup> <sup>8</sup>F-florbetapir PET/computed tomography (CT) and magnetic resonance imaging (MRI) were analyzed. CL values were generated using four US Food and Drug Administration (FDA) -cleared platforms and an in-house Centiloid standard pipeline. Agreement was assessed using intraclass correlation coefficient, with bias and limits of agreement evaluated by linear modeling and Bland-Altman analysis. Diagnostic performance was assessed using receiver operating characteristic (ROC) analysis and classification against visual interpretation.</p><p><strong>Results: </strong>Agreement was excellent (intraclass correlation coefficient [ICC] 0.969; 95%CI 0.961-0.975). Some platforms produced systematically higher CL values versus others slightly lower. LoA reached ± 30 CL. Diagnostic accuracy was high (area under the curve [AUC]: 0.949-0.975), with sensitivity 0.923-0.968 and specificity 0.667-0.806.</p><p><strong>Discussion: </strong>Despite excellent agreement, systematic differences persist and may affect classification near thresholds, supporting consistent use of a single processing pipeline.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70443"},"PeriodicalIF":4.4,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13469330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148762415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
William J B Powell, Suzanne E Schindler, Martí Jiménez-Mausbach, Inez Y Oh, Anna Hofmann, Barbara Joy Snider, Madeline Paczynski, Nupur Ghoshal, Philip R O Payne, Albert M Lai, Mackenzie R Hofford, Aditi Gupta
{"title":"Medical comorbidities of patients receiving amyloid-targeting treatments in a memory clinic.","authors":"William J B Powell, Suzanne E Schindler, Martí Jiménez-Mausbach, Inez Y Oh, Anna Hofmann, Barbara Joy Snider, Madeline Paczynski, Nupur Ghoshal, Philip R O Payne, Albert M Lai, Mackenzie R Hofford, Aditi Gupta","doi":"10.1002/dad2.70445","DOIUrl":"https://doi.org/10.1002/dad2.70445","url":null,"abstract":"<p><strong>Introduction: </strong>Trials of amyloid-targeting treatments (ATTs) for early symptomatic Alzheimer's disease (AD) enrolled selected patients with minimal medical comorbidities. We investigated whether real-world memory clinic patients who received ATTs also had fewer comorbidities than the broader clinic population.</p><p><strong>Methods: </strong>We extracted data on demographics, comorbidities, and medications from patients who were seen at the Washington University Memory Diagnostic Center from July 1, 2023, through July 1, 2025. We compared the characteristics of patients by biomarker testing status and ATT treatment status.</p><p><strong>Results: </strong>Of 9938 unique patients, 1948 underwent AD biomarker testing and 335 received ATT infusions (304 lecanemab, 31 donanemab). The patients who underwent biomarker testing or received ATTs were more likely to be White individuals and to have fewer comorbidities than patients who did not undergo testing or receive ATTs.</p><p><strong>Discussion: </strong>Real-world ATT patients were healthier than the general clinic population and more similar to clinical trial participants.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70445"},"PeriodicalIF":4.4,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13469319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148762418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Md Golam Rabbani, Sheikh M Alif, Joanne Ryan, Zhen Zhou, Cammie Tran, Amanda J Rickard, Catherine Robb, Robyn L Woods, Suzanne G Orchard, Raj C Shah, Anne M Murray, John J McNeil, Md Nazmul Karim
{"title":"Associations between serum uric acid levels and risk of dementia in community-dwelling older adults.","authors":"Md Golam Rabbani, Sheikh M Alif, Joanne Ryan, Zhen Zhou, Cammie Tran, Amanda J Rickard, Catherine Robb, Robyn L Woods, Suzanne G Orchard, Raj C Shah, Anne M Murray, John J McNeil, Md Nazmul Karim","doi":"10.1002/dad2.70440","DOIUrl":"https://doi.org/10.1002/dad2.70440","url":null,"abstract":"<p><strong>Introduction: </strong>Evidence on the association between serum uric acid (SUA) and dementia risk is inconsistent, and prospective data in older adults are limited. This study examined associations of SUA levels and trajectories with incident dementia.</p><p><strong>Methods: </strong>This study included 11,411 community-dwelling adults aged ≥70 years without dementia at baseline. Incident dementia was diagnosed using Diagnostic and Statistical Manual of Mental Disorders - Fourth Revision (DSM-IV) criteria. Sex-stratified Cox proportional hazards models assessed associations of baseline SUA and 3-year SUA changes with dementia risk.</p><p><strong>Results: </strong>Over a median 9-year follow-up, 1000 (8.8%) participants developed dementia. Low SUA levels were associated with higher dementia risk among females (age-adjusted hazard ratio [HR]: 1.31, 95% confidence interval [CI]: 1.07-1.61; fully adjusted HR: 1.24, 95% CI: 1.01-1.53), but not males. A decline in SUA over time was associated with higher dementia risk among males only (age-adjusted HR: 1.30, 95% CI: 1.03-1.63; fully adjusted HR: 1.29, 95% CI: 1.02-1.62).</p><p><strong>Discussion: </strong>Associations between SUA and dementia risk varied by sex and SUA trajectory, suggesting potential sex-specific biological mechanisms.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70440"},"PeriodicalIF":4.4,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13469351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148760202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
